| __timestamp | Bristol-Myers Squibb Company | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 381287000 |
| Thursday, January 1, 2015 | 5001000000 | 452612000 |
| Friday, January 1, 2016 | 5002000000 | 316800000 |
| Sunday, January 1, 2017 | 4849000000 | 330100000 |
| Monday, January 1, 2018 | 4551000000 | 265800000 |
| Tuesday, January 1, 2019 | 4871000000 | 336200000 |
| Wednesday, January 1, 2020 | 7661000000 | 423900000 |
| Friday, January 1, 2021 | 7690000000 | 467000000 |
| Saturday, January 1, 2022 | 7814000000 | 487000000 |
| Sunday, January 1, 2023 | 7772000000 | 477100000 |
| Monday, January 1, 2024 | 8414000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bristol-Myers Squibb Company and United Therapeutics Corporation from 2014 to 2023.
Bristol-Myers Squibb, a titan in the industry, has seen its SG&A expenses grow by approximately 36% over the decade, peaking in 2022. This increase reflects strategic investments in marketing and administration, crucial for maintaining its competitive edge. In contrast, United Therapeutics, a smaller yet formidable player, has maintained a more stable SG&A expense profile, with a modest 28% increase over the same period.
This comparison highlights the differing financial strategies of these companies, with Bristol-Myers Squibb focusing on aggressive expansion and United Therapeutics opting for steady growth. Such insights are invaluable for investors and industry analysts alike.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or United Therapeutics Corporation
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Revenue Showdown: Bristol-Myers Squibb Company vs United Therapeutics Corporation
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited and United Therapeutics Corporation: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Perrigo Company plc
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Celldex Therapeutics, Inc.